They are developing innovative products that effectively address challenging bone-related diseases and conditions. The company's proprietary bone targeting system delivers drugs to the bone surface or interior, overcoming the difficulties of accessing and treating this organ. By selectively targeting mesenchymal stem cells, their drug conjugates stimulate bone regeneration, offering a potential solution for low-bone-density disorders and enhancing bone healing. Mesentech's approach aims to improve treatment efficacy while minimizing side effects, providing a promising option for patients with difficult-to-treat bone conditions.